Condition: Follicular Lymphoma · Low Grade Non-Hodgkin's Lymphoma, Adult · Sponsor: Reid Merryman, MD
The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Rituximab (a type of monoclonal antibody therapy) * Epcoritamab (a T-cell bispecific antibody)
This description comes directly from the study's public registry record.
Reid Merryman, MD · 617-632-3352 · reid_merryman@dfci.harvard.edu
Heather A Walker, MPH · 857-215-1833 · heathera_walker@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai Hospital | New York, New York, United States | Recruiting |
| University of Rochester Medical Center | Rochester, New York, United States | Recruiting |
| The Ohio State University Wexner Medical Center | Columbus, Ohio, United States | Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05783609